Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas

NCT00070109 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00070109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00070109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
December 31, 2013
Enrollment
50 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral primitive neuroectodermal tumor, previously treated childhood rhabdomyosarcoma, recurrent childhood rhabdomyosarcoma, recurrent childhood soft tissue sarcoma, recurrent ewing sarcoma